001065.KO JW Pharmaceutical Corp
- Market cap
- KRW 648B
- P/E
- -
- P/B
- -
- ROE
- 27.0%
- Dividend yield
- 1.71%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 001065.KO undervalued?
Graham numberThe Graham number of JW Pharmaceutical Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
JW Pharmaceutical Corp fundamental analysis
No fundamental analysis for JW Pharmaceutical Corp yet.
JW Pharmaceutical Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases, and pancreatic cancer. The company also provides infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and b…
Full company profileJW Pharmaceutical Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
JW Pharmaceutical Corp annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 467B | 503B | 537B | 511B | 547B | 607B | 684B | 749B | 719B | 775B | 844B |
| Gross Profit | 173B | 189B | 197B | 161B | 178B | 234B | 288B | 336B | 323B | 359B | 407B |
| Operating Income | 24.5B | 21.7B | 21.6B | -19.0B | -1.32B | 31.2B | 62.8B | 101B | 82.7B | 94.5B | 134B |
| EBITDA | - | 26.3B | 36.6B | -2.71B | 15.1B | 44.0B | 71.6B | 90.0B | 112B | 112B | 154B |
| Net Income | -10.9B | -742M | 8.06B | -25.3B | -15.2B | -968M | 31.9B | 37.0B | 65.0B | 61.5B | 111B |
| EPS | - | -36 | 388 | -1,223 | -738 | -44 | 1,414 | 1,595 | 2,804 | 2,728 | 4,911 |
| Balance Sheet | |||||||||||
| Total Assets | 651B | 631B | 594B | 573B | 549B | 633B | 628B | 645B | 605B | 605B | 660B |
| Total Liabilities | 375B | 360B | 334B | 343B | 342B | 445B | 402B | 380B | 275B | 236B | 250B |
| Shareholders' Equity | 276B | 271B | 260B | 230B | 207B | 201B | 240B | 265B | 329B | 369B | 410B |
| Cash & Short-term Investments | 39.3B | 32.1B | 30.9B | 41.9B | 10.5B | 33.4B | 33.9B | 15.9B | 10.4B | 39.2B | 44.1B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.74B | 33.5B | 52.1B | 55.5B | 63.1B | 18.1B | 56.8B | 87.2B | 79.4B | 96.4B | 120B |
| Capital Expenditure | 10.0B | 7.50B | 8.64B | 9.28B | 12.4B | 7.47B | 9.92B | 40.7B | 28.1B | 36.1B | 22.2B |
| Free Cash Flow | - | 22.5B | 43.8B | 42.4B | 48.0B | 5.22B | 44.4B | 46.5B | 51.3B | 60.3B | 97.8B |
| Ratios | |||||||||||
| ROE | -4.0% | -0.3% | 3.1% | -11.0% | -7.3% | -0.5% | 13.3% | 13.9% | 19.7% | 16.7% | 27.0% |
| ROA | -1.7% | -0.1% | 1.4% | -4.4% | -2.8% | -0.2% | 5.1% | 5.7% | 10.8% | 10.2% | 16.8% |
| Net Profit Margin | -2.3% | -0.1% | 1.5% | -4.9% | -2.8% | -0.2% | 4.7% | 4.9% | 9.0% | 7.9% | 13.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
JW Pharmaceutical Corp dividends
- Dividend yield
- 1.71%
- Forward dividend
- 675.00 KRW
- Payout ratio
- 18.0%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 11.1B | 491 | 18.0% |
| 2024 | KRW 9.67B | 417 | 14.9% |
| 2023 | KRW 8.81B | 380 | 23.8% |
| 2022 | KRW 7.35B | 326 | 23.1% |
| 2021 | KRW 7.15B | 326 | - |
| 2020 | KRW 6.95B | 337 | - |
| 2019 | KRW 6.82B | 330 | - |
| 2018 | KRW 6.51B | 314 | 80.8% |
| 2017 | KRW 5.88B | 284 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.02:1 on Dec 27, 2023.
Who owns JW Pharmaceutical Corp
Ownership data of JW Pharmaceutical Corp is not available yet.
JW Pharmaceutical Corp company profile
- Company name
- JW Pharmaceutical Corp
- Ticker
- 001065.KO
- ISIN
- KR7001061001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,049
- Fiscal year end
- December
- Address
- JW Gwacheon Tower, 38, Gwacheon-si, South Korea, 13840
- Phone
- 82 2 840 6777
- Website
- jw-pharma.co.kr
About JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases, and pancreatic cancer. The company also provides infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is based in Gwacheon-si, South Korea.
JW Pharmaceutical Corp management
5- Mr. Young-Sub ShinCEO, Head of Sales & Marketing and Inside Director · born 1963
- Sung-Yeol LeeCEO, Head of Product Development & Management and Director
- Jae-Kwang JeonHead Managing Director and Head of Public Relation · born 1962
- Mr. Hyun-seok HanHead of Product Plant · born 1962
- Kim Yong KwanDevelopment Head & Internal Director